Endocrine Abstracts

A 53-year-old man was referred for assessment of diabetes insipidus. He had been treated with intranasal desmopressin from18 months of age on the basis of an extensive family history but without confirmatory testing. The current referral was because of hyponatraemia in a similarly affected relative, which had raised uncertainty about diagnosis and treatment.The family history included 11 affected individuals across four generations and suggested autosoma...

Radioiodine is the treatment of choice for relapsed hyperthyroidism although the optimum protocol is uncertain. We assessed the outcome of therapy with 131I in relapsed hyperthyroidism using a fixed dose regimen.We retrospectively studied 449 patients (M: F 82: 367; age range 13–89 y, median 42 y) treated between 2003 and 2007 with a fixed dose of 550 MBq 131I for relapsed hyperthyroidism. Patients were classified as either Gra...

Dopamine agonist therapy is an effective long-term treatment in >90% of patients with hyperprolactinaemia, controlling both prolactin secretion and tumour growth. We describe the unusual late emergence of resistance to high-dose dopamine agonist treatment in two recent female patients. Both women presented with secondary amenorrhoea, were shown to have high prolactin levels and a pituitary microadenoma. Each had an excellent initial response to bromocriptine but years late...

Altered adipokine levels may explain the link between obesity and insulin resistance. One potential candidate is retinol binding protein 4 (RBP4) which is elevated in type 2 diabetes and correlates with the magnitude of insulin resistance. Low adiponectin levels are also associated with insulin resistance. Adiponectin circulates in multimeric complexes and multimer distribution may also be important.We measured RBP4 and adiponectin multimers in 24 obese ...